Perspective Therapeutics, Inc. Operating Income Loss

• Perspective Therapeutics, Inc. showed a decrease of -25.0% in Operating Income Loss from 2024 to 2025.
• This data is from Perspective Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
• XBRL data for this metric is available from 2012 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 15 years of available data (2012 to 2025), Perspective Therapeutics, Inc.'s Operating Income Loss has declined by 3,056.3%.
• Historical annual values: Fiscal year 2025: -$113.56 million | Fiscal year 2024: -$90.89 million | Fiscal year 2023: -$40.94 million | Fiscal year 2022: -$8.67 million | Fiscal year 2022: -$6.42 million | Fiscal year 2021: -$3.45 million | Fiscal year 2020: -$3.48 million | Fiscal year 2019: -$5.25 million | Fiscal year 2018: -$6.73 million | Fiscal year 2017: -$6.31 million | Fiscal year 2016: -$5.08 million | Fiscal year 2015: -$4.34 million | Fiscal year 2014: -$4.59 million | Fiscal year 2013: -$4.07 million | Fiscal year 2012: -$3.60 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026